profit from every $100 of sales.
$0$100
Reviva Pharmaceuticals Holdings
$0.34+0.03% today
-96.8% in 1 year
1-year low $0.321-year high $14.60
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Reviva Pharmaceuticals Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$19.9 million of profit last year.
SalesProfit
Reviva Pharmaceuticals Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Reviva Pharmaceuticals Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -28 | -40 | -31 | -20 | |
| -28 | -39 | -30 | -20 | |
| -28 | -39 | -30 | -20 | |
| -25.00 | -33.00 | -18.00 | -5.48 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 19 | 24 | 16 | 16 |
| Cash | 19 | 23 | 13 | 14 |
| Total debt | – | – | 0 | 0 |
| Total liabilities | 11 | 18 | 15 | 7 |
| 8 | 6 | 1 | 9 | |
| 1 | 1 | 2 | 4 | |
| -265.7% | -541.7% | -1,857.7% | -173.0% | |
| -336.7% | -686.5% | -3,682.0% | -229.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -28 | -34 | -25 | |
| – | – | – | – | |
| -19 | -28 | -34 | -25 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- 1.2×
- –
- –
- 0.7×
- -551.6%
- -445.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -177.4%
- -727.5%
- -918.9%
- -124.8%
- -233.6%
- –
Growth
- –
- –
- −73,320,626.8%
- –
- +54.9%
Financial health
- 0.7×
- 0.05
- 2.6%
- -1,479.8×
- 2.08
- 2.08
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.46 | -0.36 | −29.6% |
| Mar 30, 2026 | 0.72 | -1.08 | +166.7% |
| Nov 13, 2025 | -0.06 | -0.11 | +45.5% |
| Aug 14, 2025 | -0.12 | -0.15 | +20.0% |
| May 15, 2025 | -0.13 | -0.21 | +38.1% |
| Mar 31, 2025 | -0.15 | -0.22 | +31.8% |
| Nov 14, 2024 | -0.25 | -0.23 | −8.7% |
| Aug 14, 2024 | -0.26 | -0.28 | +7.1% |
News
Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23Seeking Alpha · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
61Pass
Philip Fisher
34No pass
Peter Lynch
59No pass
Joel Greenblatt
50No pass
Charlie Munger
29No pass
Terry Smith
32No pass
Questions about Reviva Pharmaceuticals Holdings
Is Reviva Pharmaceuticals Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Reviva Pharmaceuticals Holdings AI analysis
What does Reviva Pharmaceuticals Holdings do?
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. It is in Biotechnology.
Does Reviva Pharmaceuticals Holdings pay a dividend?
No. Reviva Pharmaceuticals Holdings does not pay a dividend at the moment.
Is Reviva Pharmaceuticals Holdings stock halal?
No. Reviva Pharmaceuticals Holdings does not pass our halal screen: its cash and confirmed interest-bearing investments are 324% of its market value, at or above the 33% limit. How we check
How has Reviva Pharmaceuticals Holdings stock done over the past year?
Down 96.8% over the past twelve months, to $0.34. It traded between $0.32 and $14.60 and is 97.7% below its high.
Who are Reviva Pharmaceuticals Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Reviva Pharmaceuticals Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.